SRT1720 HCl, |
1001645-58-4 |
|||||||||
|
|
|
Cat.No.: |
IC-0235868 |
|
|
|
|||
Product Information |
||||||||||
Biological Activity |
||||||||||
SRT1720 is a small-molecule compound which has the ability of activating the sirtuin subtype SIRT1 in vitro. The activity of SRT1720 as a SIRT1 activator is stronger than that of resveratrol. It affects mitochondrial respiration in a Sirt1- and PGC-1¦Á-dependent manner. SRT1720 has been demonstrated to enhance insulin sensitivity and improve measures of mitochondrial capacity and oxidative metabolism. Treatment of multiple myeloma (MM) cells with SRT1720 inhibits growth and induced apoptosis in MM cells resistant to conventional and bortezomib therapies without significantly affecting the viability of normal cells. SRT1720 is able to enhance the cytotoxic activity of bortezomib or dexamethasone. Anti-MM activity of SRT1720 is related to: 1) activation of caspase-8, caspase-9, caspase-3, poly(ADP) ribose polymerase; 2) increase in reactive oxygen species; 3) induction of phosphorylated ataxia telangiectasia mutated/checkpoint kinase 2 signaling; 4) decrease in vascular endothelial growth factor-induced migration of MM cells and associated angiogenesis; and 5) inhibition of nuclear factor-¦ÊB. |
||||||||||
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines) |
||||||||||
Species |
Mouse |
Rat |
Rabbit |
Guinea pig |
Hamster |
Dog |
||||
Weight (kg) |
0.02 |
0.15 |
1.8 |
0.4 |
0.08 |
10 |
||||
Body Surface Area (m2) |
0.007 |
0.025 |
0.15 |
0.05 |
0.02 |
0.5 |
||||
Km factor |
3 |
6 |
12 |
8 |
5 |
20 |
||||
Animal A (mg/kg) = Animal B (mg/kg) multiplied by (Animal B Km / Animal A Km) |
||||||||||
Order Information |
||||||||||
|
Quantity |
Price($£© |
Price(€) |
Price(£¤/CNY£© |
Price(£¤/JYP£© |
|||||
10mg |
$222.80 |
€267.36 |
£¤2,228.00 |
¥44,337.20 |
||||||
100mg |
$950.00 |
€1,140.00 |
£¤9,500.00 |
¥189,050.00 |
||||||
500mg |
$4,293.00 |
€5,151.60 |
£¤42,930.00 |
¥854,307.00 |
||||||
|
Free Delivery on orders over $350.00. |
|||||||||
Chemical Information |
||||||||||
Molecular Weight |
506.02 |
|||||||||
Formula |
C25H23N7OS.HCl |
|||||||||
CAS Number |
1001645-58-4 |
|||||||||
Purity |
>98% |
|
|
|
|
|
||||
Solubility |
100 mg/mL in DMSO |
|||||||||
Storage |
at -20¡ãC |
|
|
|
|
|
||||
Reference |
||||||||||
[1]Robin K. Minor, Joseph A. Baur, Ana P. Myriam Gorospe, Josephine M. Egan, Mark I. Talan, Johan Auwerx, Christoph H. Westphal, James L. Ellis, Zoltan Ungvari, George P. Vlasuk, Peter J. Elliott, David A. Sinclair, Rafael de Cabo. SRT1720 improves survival and healthspan of obese mice. Scientific Reports. 2011; 1(70): 1038 ¨C 1131. |
||||||||||
[2]Kensuke Suzuki, Ryuji Hayashi, Tomomi Ichikawa, Shingo Imanishi, Toru Yamada, Minehiko Inomata, Toshiro Miwa, Shoko Matsui, Isao Usui, Masaharu Urakaze, Yuji Matsuya, Hirofumi Ogawa, Hiroaki Sakurai, Ikuo Saiki, Kazuyuki Tobe. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncology reports. 2012; 27: 1726 -1732. |
||||||||||
[3]Dharminder Chauhan, Madhavi Bandi, Ajita V. Singh, Arghya Ray, Noopur Raje, Paul Richardson and Kenneth C.Anderson. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. British Journal of Haematology. 2011; 155: 588¨C598. |
||||||||||
We Devoted Ourselves To The Development Of Biomedical Research Reagent. |
||||||||||